Interventional Oncology Devices – Market Insights – Europe

The European interventional oncology device market will see moderate growth through 2032, driven by improved reimbursement, increasing popularity of minimally invasive surgeries, and growing physician acceptance of interventional oncology procedures. However, growth in this market will be hindered by mixed clinical data, increasing-price competition, and ongoing cost constraints in the region.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for interventional oncology devices in Europe from 2019 to 2032.

Overcoming the short-term consequences that COVID-19 pandemic has had on the interventional oncology devices, the market has begun to see recovery toward prepandemic levels.

Which procedure types were impacted the most by COVID-19?

What will recovery look like for different procedure categories over the forecast period?

The ablation device market is dominated by microwave ablation; however, new technologies are increasingly being used.

How has the adoption of cryoablation changed the market dynamics in the microwave and RF ablation device segments?

What are the strategies employed by key competitors to position themselves in this market, and what challenges do they face?

Which major clinical trials are being conducted, and how will they impact the interventional oncology device market?

Ablation therapy procedures will continue to grow for the liver, kidney, and lung cancer indications, while novel indications such as prostate and pancreatic cancer represent new opportunities for growth.

What are the advantages and disadvantages of each type of ablation device offered by competitors, and how do these differences affect adoption for different indications?

What are the major demographic, economic, and local trend differences across Europe that impact the adoption of these devices?

How will growth vary across different ablation device categories?

Newer embolization technologies are seeing increasing adoption.

How will the market growth vary across different embolization device categories?

What is the adoption outlook for different embolization devices, and what factors will affect the penetration of these technologies over the forecast period?

What impact will clinical guidance have on the adoption of newer technologies in the embolization device market?

How will the adoption of DEBs and radioembolization spheres be affected by recent clinical trials?

Table of contents